Pregnenolone as a Treatment for Cannabis Intoxication
Johns Hopkins University
20 participants
Apr 24, 2026
INTERVENTIONAL
Conditions
Summary
The present study will characterize the ability of pregnenolone to reverse the acute intoxication and associated symptoms of cannabis. Healthy adults with a history of cannabis use will be recruited to participate in a placebo-controlled, within-subject crossover study at Johns Hopkins Behavioral Pharmacology Research Unit (BPRU). By clarifying the ability of pregnenolone to reverse cannabis intoxication symptoms, this study will pave the way for larger clinical studies that provide a foundation for the development of future CB1-receptor NAM medications that could be applied in emergency situations and potentially validate pregnenolone as a treatment for cannabis intoxication.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Cannabis brownie, 25mg THC
Pregnenolone, low dose, one 250mg pregnenolone capsule and one 0 mg pregnenolone capsule
Pregnenolone, high dose, two 250 mg pregnenolone capsules
Placebo capsule, 0mg
Placebo brownie, 0mg THC
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07216690